1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Cytokinetics Seeks ALS Success By Focusing On Lung Function

 
• By Joseph Haas

Despite an earlier Phase II failure on broader ALS endpoint, biotech thinks it can demonstrate efficacy in slowing lung-function decline in ALS patients.

Backed both with funding from ALS Association's Ice Bucket Challenge proceeds and from an expanding partnership with Astellas Pharma Inc., Cytokinetics Inc. thinks it may succeed where others have failed in amyotrophic lateral sclerosis, with a drug that has demonstrated ability to slow the decline of lung function, the primary cause of death in most ALS patients.

The South San Francisco, Calif.-based firm announced that its Phase III VITALITY-ALS trial had completed global enrollment of about 700...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapy Areas

Obesity Beyond GLP-1s: Amylins – The Next Frontier

 
• By Aakash Babu

In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. First on our list – amylin receptor agonists, which analysts expect to grow into a $50bn market opportunity.

Dispatch Uses ‘Flare’ To Send CAR-Ts To Solid Tumors

 
• By Alaric DeArment

With $216m in initial funding, the newly launched company is aiming to develop a cell therapy-based universal immuno-oncology option for solid tumor indications.

Where Next For Biologics In COPD After Roche’s Astegolimab Phase III Missfire?

 
• By Sushmita Panda

The Phase III failure could dent Roche’s hopes of entering the COPD market with its novel therapy, despite its success in a large Phase IIb trial. It also marks another disappointment for the anti-IL33/ST2 approach.